From vaccines to cancer therapy, biologics are transforming how we treat disease. They don’t just reduce symptoms. They target the root cause. Let's dive in depth. What Are Biologics? Biologics are medicines derived from living cells or biological materials. Unlike drugs such as Aspirin or Ibuprofen, which are made using chemicals, biologics are produced inside…

The FDA approved 5 drugs in March 2026. The approved drugs span across fields like hepatology, dermatology, oncology, rare genetic disorders, and diabetes. These approvals hint at valuable opportunities for generic and biosimilar developers. For pharmaceutical companies focused on Para IV filings, aBLA pathways, and portfolio expansion, early visibility into NCE-1 timelines, data exclusivity, and…

With 1 drug approved in January 2026, we saw a great hike in the approval of drugs in the month of February. In January, the orphan drug Zycubo was approved, whereas in the month of February, 4 drugs were approved. These approvals span multiple therapeutic areas with varied significance: Dermatology Psychiatry Rare Metabolic Disorders Growth…

Understanding when a generic or biosimilar opportunity truly opens is rarely straightforward. Regulatory exclusivity and patent protection follow different timelines, and confusing them can lead to costly strategic mistakes. For companies planning generic (ANDA/Para IV) or biosimilar (aBLA) development, understanding how these timelines interact is critical. Misinterpreting them can delay development planning, affect filing strategies,…

The rare disease landscape has hit a significant milestone early in 2026. On January 12th, the FDA announced the approval of ZYCUBO (Copper Histidinate), marking a historic shift in the treatment of Menkes disease and a high-stakes entry for pharmaceutical developers. For strategic planners, this isn't just a clinical win; it’s an opportunity to navigate…

One wrong decision when selecting an enteral feeding tube supplier can disrupt patient care overnight. Enteral feeding tube supplies are not a standard procurement decision. For patients who cannot swallow due to neurological disorders, cancer, feeding disabilities, or severe illness, these tubes are how they receive nutrition and medication every single day. Clinical studies estimate…

In 2025, the US FDA approved 11 New Biological Entities (NBEs), representing a significant milestone in biologics innovation. The NBE landscape showcases the power of biologics across high-value therapeutic areas, with several molecules projected to reach multi-billion-dollar sales by 2031. Oncology dominates the NBE approvals, but immunology, respiratory, cardiovascular (lipid disorders), and rare disease therapies…

In 2025, the US FDA approved 45 new drugs, including 34 New Chemical Entities (NCEs) and 11 New Biological Entities (NBEs), highlighting a strong and diverse innovation pipeline. Oncology continues to lead approvals, but significant momentum is also seen in cardiovascular, metabolic, respiratory, immunology, and anti-infective therapies, signaling broad-based investment across therapeutic areas. Several newly…

In pharmaceutical development, choosing the right regulatory pathway can significantly influence timelines, costs, and overall program success. The 505(b)(2) pathway has emerged as a strategic option for companies aiming to develop differentiated drug products more efficiently. It allows innovators to develop a new drug without repeating studies that have already been proven. What Is The…

Every breakthrough medication starts somewhere. That somewhere is either a New Chemical Entity (NCE) or a New Biological Entity (NBE). But what's the difference? And why does it matter for clinical trial supply and drug development? What is a New Chemical Entity (NCE)? An NCE is a small-molecule drug with a unique chemical structure. It…